Literature DB >> 721941

Assessment of availability and efficacy of commercial Salmonella grouping antisera.

G M Evins, L L Linne, H M Colvin.   

Abstract

Salmonella somatic antisera for groups A to E were purchased from four commercial producers directly by the Center for Disease Control (CDC) and indirectly through two hospitals. CDC specifications and methods were used to evaluate antisera shipped directly to CDC. To assess the performance of the products under simulated user conditions, we used the commercial antisera purchased indirectly through the hospitals to group coded cultures. Of the 23 antisera ordered by CDC and the hospitals, the CDC received all 23, a large medical complex received 20, and a private hospital received 9. Similar results were obtained with producer and CDC test methods. Forty-five different lots of antisera were evaluated, of which 20% did not meet CDC specifications. The CDC specifications and latest revisions are discussed.

Mesh:

Substances:

Year:  1978        PMID: 721941      PMCID: PMC275254          DOI: 10.1128/jcm.8.4.360-368.1978

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  2 in total

1.  Evaluation of commercial Salmonella O polyvalent and Vi antisera.

Authors:  G M Evins; L L Linne; H M Colvin
Journal:  J Clin Microbiol       Date:  1976-10       Impact factor: 5.948

2.  [Study on the antigenic relationships between the group O:54 and other groups O of Salmonella].

Authors:  L Le Minor; R Rohde; C Charié-Marsaines; C Coynault
Journal:  Ann Inst Pasteur (Paris)       Date:  1971-10
  2 in total
  1 in total

1.  Coagglutination as an expedient for grouping Escherichia coli associated with urinary tract infections.

Authors:  D L Hovanec; E A Gorzynski
Journal:  J Clin Microbiol       Date:  1980-01       Impact factor: 5.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.